McCall and her team are expanding services across the U.S.making it easier than ever to access expert thyroid care, no matter your zip code
Endocrine 27 , 111118 (2005)

Back to Journals Diabetes, Metabolic Syndrome and Obesity Volume 10 Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway Authors Civantos E, Bosch E, Ramirez E, Zhenyukh O, Egido J, Lorenzo O, Mas S Received 17 January 2017 Accepted for publication 22 March 2017 Published 7 June 2017 Volume 2017:10 Pages 207222 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Professor Ming-Hui Zou Esther Civantos, 1,2 Enrique Bosch, 1 Elisa Ramirez, 1 Olha Zhenyukh, 1 Jess Egido, 1,2 Oscar Lorenzo, 1,2 Sebastin Mas 1,2 1 Renal, Vascular and Diabetes Research Laboratory, IIS-Fundacin Jimnez Daz, Autonoma University, 2 CIBERDEM (Biomedical Research Centre in Diabetes and Associated Metabolic Disorders), Madrid, Spain Background: Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used in type 2 diabetes therapy, has demonstrated protective effects in diabetic chronic kidney disease, in part due to its pleiotropic actions

Lower doses of semaglutide (0.1 and 0.3 mg/kg) reduced chow intake but not sucrose intake nor VTA dopamine activity in the task